article thumbnail

Race to the finish: pharma edges closer to approval with RSV vaccines

Pharmaceutical Technology

RSV researchers at major pharmaceutical companies are currently working to develop new RSV drugs to beat future waves of RSV infection and gain the first RSV vaccine FDA approval. Pharmaceutical companies are pushing to develop drugs and vaccines for RSV with these populations in mind.

article thumbnail

Seamless Integration with Any Automation Environment

ISPE

A landmark project for a major international pharmaceutical company was the starting point for a series of follow-up projects in Switzerland and Germany. . Biopharmaceutical active ingredients, such as anti-cancer drugs, insulin, vaccines and infusions are produced in these highly complex, "tailor-made" facilities.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

GSK, Sanofi and Takeda join AI and robotics push for Singapore biomanufacturing

Pharmaceutical Technology

The Singapore Government has launched Biologics Pharma Innovation Programme Singapore (BioPIPS), which aims to increase the country’s manufacturing capacity for biologics, including recombinant proteins and vaccines. The organizations plan to use data analytics to improve manufacturing processes. Additionally, Merck & Co.

Vaccines 105
article thumbnail

Cerba Research and Teddy Lab sign Memorandum of Understanding on entering into a discussion for Joint Venture

Pharmaceutical Technology

During the pandemic, Teddy Lab Wuxi have supported over dozens of COVID drug or vaccine clinical trials, many of which are working closely with Cerba Research, and as a result, multiple candidates have been approved under emergency use in different countries. Teddy Lab also reached multiple milestones in the past 5 years.

article thumbnail

Pharma’s post-pandemic launch performance problem: what’s the prognosis?

pharmaphorum

COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. The prescription medicine market has recovered from the wild swings of the early pandemic with renewed growth. appeared first on.

article thumbnail

The impact of clinical trial decentralisation on the pharma supply chain

Pharmaceutical Technology

The global vaccine rollout would never have taken place without the advances in visibility and control over supply chains that it necessitated. Shoring these up will be a prerequisite for ushering in the age of decentralised pharmaceuticals. But it also ramped up adoption of decentralisation by highlighting its value.

article thumbnail

The impact of clinical trial decentralisation on the pharma supply chain

Pharmaceutical Technology

The global vaccine rollout would never have taken place without the advances in visibility and control over supply chains that it necessitated. Shoring these up will be a prerequisite for ushering in the age of decentralised pharmaceuticals. But it also ramped up adoption of decentralisation by highlighting its value.